Background
Bronchiectasis is increasingly recognized as a major cause of respiratory morbidity especially in developing countries. Even in affluent countries, bronchiectasis is increasingly seen in some community subsections (e.g. Aboriginal communities) and occurs as a comorbidity and disease modifier in respiratory diseases such as chronic obstructive pulmonary disease (COPD). Respiratory exacerbations in people with bronchiectasis are associated with reduced quality of life, accelerated pulmonary decline, hospitalisation and even death. Conjugate pneumococcal vaccine is part of the routine infant immunisation schedule in many countries. Current recommendations for additional pneumococcal vaccination include children and adults with chronic suppurative disease.
Objectives
To evaluate the effectiveness of pneumococcal vaccine as routine management in children and adults with bronchiectasis in (a) reducing the severity and frequency of respiratory exacerbations and (b) pulmonary decline.
Search strategy
The Cochrane Register of Controlled Trials (CENTRAL), the Cochrane Airways Group Specialised Register, MEDLINE and EMBASE databases were searched by the Cochrane Airways Group. Pharmaceutical manufacturers of pneumococcal vaccines were also contacted. The latest searches were performed in November 2007.
Selection criteria
All randomised controlled trials that utilised pneumococcal vaccine on children and adults with bronchiectasis. All types of pneumococcal vaccines were included.
Data collection and analysis
Results of searches were reviewed against pre-determined criteria for inclusion. No eligible trials were identified and thus no data was available for analysis. One small non-randomised controlled trial in children was reported.
Main results
No randomised controlled trials pertaining effectiveness of pneumococcal vaccine as routine management in children and adults with bronchiectasis were found. A benefit in elimination of Strep. pneumoniae in the sputum was found in a non-randomised trial in children but no clinical effect was described.
Authors' conclusions
At present, there is a lack of reliable evidence to support or refute the routine use of pneumococcal vaccine as routine management in children and adults with bronchiectasis. Randomised controlled trials examining the efficacy of this intervention using various vaccine types in different age groups are needed. Until further evidence is available, it is recommended that health providers adhere to national guidelines.
P L A I N L A N G U A G E S U M M A R Y

Pneumococcal vaccines for children and adults with bronchiectasis
In many countries vaccination for the protection against infection of the bacteria pneumococcus, is part of the immunisation schedule for infants as well as, for people with bronchiectasis. In this review, our search for randomised control trials that examined the effectiveness of pneumococcal vaccines for people with bronchiectasis revealed no relevant studies. We thus cannot draw any conclusions for, or against, the routine pneumococcal vaccinations in people with bronchiectasis. However, we would recommend that national guidelines be followed until further evidence is available.
B A C K G R O U N D
Bronchiectasis, previously termed an 'orphan's disease' is increasingly recognized as a major cause of respiratory morbidity especially in developing countries (Karadag 2005) and in pockets of affluent countries (Edwards 2003 , Singleton 2000 . Of diverse aetiology, bronchiectasis is often a result of repeated respiratory infections or may be due to rare immune deficiencies. Increasingly recognised as a common final pathway for a variety of diseases, it is seen to complicate both common and uncommon respiratory illnesses such as COPD, bronchiolitis obliterans and sar- The dominant symptoms and signs of bronchiectasis are a productive or wet cough, dyspnoea on exertion and presence of other respiratory signs (clubbing, chest wall deformity, respiratory noises such as wheeze or crepitations on auscultation). In the long term, pulmonary decline may occur (Keistinen 1997, Twiss 2006). Children and adults with bronchiectasis suffer from recurrent acute exacerbations, some necessitating inpatient care. Effective management regimes for bronchiectasis should improve quality of life, reduce the frequency and severity of respiratory exacerbations and rate of pulmonary decline. Cole's 'vicious circle hypothesis' suggests microbial colonization or infection as a key factor in its pathophysiology as this often leads to bronchial obstruction and a normal or exaggerated inflammatory response (Cole 1986). Treatment modalities that prevent or limit respiratory infections should thus, prevent or reduce respiratory decline. 
O B J E C T I V E S
M E T H O D S Criteria for considering studies for this review Types of studies
All randomised controlled trials using pneumococcal vaccine in patients with bronchiectasis.
Types of participants
Adults or children with bronchiectasis (defined clinically or radiologically). Exclusion criteria: Participants with other diseases where bronchiectasis is not present.
Types of interventions
Types of outcome measures
Attempts were made to obtain data on at least one of the following outcome measures: (A) for short term effectiveness (12 months or less) a) proportions of participants who had respiratory exacerbations b) proportions of participants who were hospitalised, c) total numbers of days with respiratory symptoms d) total number of hospitalised days e) mean difference in bronchiectasis severity control (QOL, cough diary, Likert scale, visual analogue scale, level of interference of cough, cough diary, etc), f ) proportions experiencing adverse effects of the intervention, (e.g. local reaction, exacerbation immediately post vaccination, systemic effects (myalgia, fever, fatigue), etc) Outcomes (a) to (e) will be examined globally as well as also specifically to proven pneumococcal infections (from airway specimens or rising titres) (B) for medium to long term outcomes (more than 1 year) g) radiology scores (high resolution computed tomography scans or chest radiograph) h) lung function i) bronchiectasis severity control (QOL, cough diary, Likert scale, visual analogue scale, level of interference of cough, cough diary, etc), j) relevant airway markers of inflammation. k) other non-respiratory outcomes (otitis media, bacteraemia, meningitis, etc) caused by pneumococcus.
Search methods for identification of studies
The following topic search strategy was used to identify relevant randomised controlled trials from electronic databases:
("bronchiectasis" OR "suppurative lung disease") AND ((vaccin* OR immunis*) AND (pneum*)) (all as textword or index terms). For the full strategies see Table 1 Trials were identified from the following sources: 
Data collection and analysis
Retrieval of studies: From the title, abstract, or descriptors, two reviewers (CC, AC) independently reviewed literature searches to identify potentially relevant trials for full review. Searches of bibliographies and texts were conducted to identify additional studies. From the full text using specific criteria, the same two reviewers independently selected trials for inclusion. Agreement would have been measured using kappa statistics. Disagreement would have been resolved by adjudication (RS and PM). It was planned that trials that satisfied the inclusion criteria would have been reviewed and the following information recorded: study setting, year of study, source of funding, patient recruitment details (including number of eligible subjects), inclusion and exclusion criteria, other symptoms, randomisation and allocation concealment method, numbers of participants randomised, blinding (masking) of participants, care providers and outcome assessors, dose and type of intervention, duration of therapy, co-interventions, numbers of patients not followed up, reasons for withdrawals from study protocol (clinical, side-effects, refusal and other), details on side-effects of therapy, and whether intention-to-treat analyses were possible. Data would have been extracted on the outcomes described previously. While only the allocation concealment quality assessment would have been displayed in the meta-analysis figures, all assessments would have been included in the "Characteristics of included studies" table. Inter-reviewer reliability for the identification of high quality studies for each component would have been measured by the Kappa statistic. STATISTICS It was planned that the results from studies that met the inclusion criteria and reported any of the outcomes of interest would have been included in the subsequent meta-analyses. The summary weighted odds ratio and 95% confidence interval (fixed effects model) would have been calculated (Cochrane statistical package, RevMan version 4.2). For cross-over studies, mean treatment differences would have been calculated from raw data, extracted or imputed and entered as fixed effects generic inverse variance (GIV) outcome, to provide summary weighted differences and 95% confidence intervals. Numbers needed to treat (NNT) would have been calculated from the pooled OR and its 95% CI applied to a specified baseline risk using an online calculator (Cates 2003). If studies reported outcomes using different measurement scales, the standardised mean difference would have been estimated. Any heterogeneity between the study results would have been described and tested to see if it reached statistical significance using a chisquared test. The 95% confidence interval estimated using a random effects model would have been included whenever there are concerns about statistical heterogeneity.
SUB-GROUP ANALYSIS:
The following a priori sub-group analyses was planned: 1. children (aged 18 years or less) and adults (>18 years) 2. types of pneumococcal vaccine 3. type of control group 4. participant type (bronchiectasis as primary disease vs bronchiectasis as co-existent disease) 5. severity of bronchiectasis (based on lung function) Sensitivity analyses were also planned to assess the impact of the potentially important factors on the overall outcomes: a) study quality; b) variation in the inclusion criteria; c) differences in the medications used in the intervention and comparison groups; d) differences in outcome measures; e) analysis using random effects model; f ) analysis by "treatment received"; and g) analysis by "intention-to-treat".
Description of studies
See: Characteristics of excluded studies. The searches identified 3 potentially relevant publications but none fulfilled the study eligibility criteria (see Table of excluded studies).
Risk of bias in included studies
Not applicable as there were no eligible studies.
Effects of interventions
The Airways Group specialised register/search identified 44 potentially relevant titles. After assessing the abstracts, 3 publications were considered for inclusion into review including one non-English article (Russian). No additional studies were found in the review articles. No additional data were available from the two pharmaceutical companies contacted (Merck Sharp & Dohme and Wyeth in Australia). The only study in patients with bronchiectasis where a comparative group was used, was a non-randomised study in Russian (Ryzhov 2005) . In this study (Ryzhov 2005) in children with chronic lung disease (including bronchiectasis), 25 were vaccinated with PPV23, 13 with Haemophilus influenzae vaccine and 40 children were not vaccinated. The authors described that, a year after vaccination with PPV23, S. pneumoniae were isolated in monoculture in 3 out of 25 cases (88% elimination) (Ryzhov 2005 ). An update search run in November 2007 did not identify any additional studies.
D I S C U S S I O N
No randomised controlled trials comparing the effectiveness of pneumococcal vaccine as routine management in children and adults with bronchiectasis were identified.
In the target group examined in this Cochrane review, the one controlled study identified was not randomised (Ryzhov 2005); this study described efficacy with respect to microbiology of the sputum but clinical evaluation was not examined.
Large trials and meta-analysis have demonstrated that pneumococcal vaccination protects children and adults from invasive pneumococcal disease (de Roux 2005), thus many recommendations exist for regular pneumococcal vaccination for those at risk (including patients with suppurative lung disease). This Cochrane review however illustrates the glaring lack of evidence to support or refute these recommendations in the target group of people with bronchiectasis. Whilst we cannot always "wait for perfect data", others have cautioned against "availability creep" with respect to the gap between policy and evidence (Jefferson 2006). Until RCTs are undertaken to examine the question, we cannot be confident whether routine pneumococcal vaccination in children and adults with bronchiectasis is beneficial. The feasibility of performing RCTs in this target group is in question. For now, as children and adults with bronchiectasis are at increased risk for pneumonia and pneumococcal disease and there is some evidence that pneumococcal vaccine can reduce pneumonia and invasive pneumococcal disease (Lucero 2004), it would be prudent that providers follow guidelines from the national bodies such as Advisory Committee on Immunization Practices (in USA) (ACIP) and NIPS (Australia) (NIPS) regarding recommendations for pneumococcal vaccination of persons with bronchiectasis.
A U T H O R S ' C O N C L U S I O N S Implications for practice
There is a lack of evidence for or against, routine additional pneumococcal vaccination for children and adults with bronchiectasis specifically. Circumstantial data suggests that pneumococcal vaccination is beneficial. As children and adults with bronchiectasis are at increased risk for pneumonia and pneumococcal disease and there is evidence that pneumococcal vaccine can reduce pneumonia and invasive pneumococcal disease, it would be prudent that providers follow national guidelines regarding recommendations for pneumococcal vaccination of persons with bronchiectasis. Individual risk factors for adverse events should be taken into account.
Implications for research
Randomised controlled trials to establish the efficacy of pneumococcal vaccination in reducing severity and frequency of respiratory exacerbations and pulmonary decline in people with bronchiectasis are needed. As vaccine response alters with age, age-based cohorts should include young children (less than 2 years), children, adults and older adults. Various vaccine types and microbiological surveillance for possible serotype replacement should also be examined in these RCTs. However the difficulty in performing a RCT in the target group is acknowledged.
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